Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19317370 | 0.86 | PGK1 (0.34) | RPS6KB1NR3C1PGRNR3C2 | |
| SCHEMBL17571471 | 0.76 | KMT2A (0.41) | RPS6KB1NR3C1PGRNR3C2 | |
| SCHEMBL11983503 | 0.76 | NOS1 (0.43) | RPS6KB1NTRK1NTRK3NTRK2NR3C1 | |
| SCHEMBL17896880 | 0.73 | MAP4K4 (0.44) | RPS6KB1NTRK1NTRK3NTRK2NR3C1 | |
| SCHEMBL16355201 | 0.72 | RPS6KB1 (0.37) | RPS6KB1NTRK1NTRK3NTRK2NR3C1 | |
| SCHEMBL15587611 | 0.72 | MAP4K4 (0.42) | RPS6KB1NTRK1NTRK3NTRK2NR3C1 | |
| SCHEMBL14570491 | 0.71 | ACHE (0.39) | RPS6KB1NR3C1PGRNR3C2RAPGEF4 | |
| SCHEMBL15840092 | 0.70 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL13777371 | 0.70 | LMNA (0.52) | — | |
| SCHEMBL18251695 | 0.69 | ERCC1 (0.50) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | RPS6KB1 1099/4885NTRK1 1198/4885NTRK3 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.